Ranibizumab Treatment for Retinal Vein Occlusion

Sponsor: Kyoto University, Graduate School of Medicine
Study ID: NCT01968616
Status: Unknown

Conditions

Macular Edema Due to BRVO/CRVO

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Ranibizumab, 0.5mg, Intravitreal — DRUG

Study Details

In retinal vein occlusion, predictive factors for visual outcome after ranibizumab treatment have not been evaluated comprehensively. Therefore, we have planned to analyze predictors for visual outcome from a viewpoint of electrophysiology and biomarkers besides morphological features by SD-OCT.

Key Dates

First listed: Oct 24, 2013
Start date: Sep 30, 2013
Status verified: Mar 2017
Primary completion: Sep 30, 2019
Completion: Sep 30, 2019

Study Design

Enrollment: 100 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Other: Intravitreal Lucentis 0.5mg
One arm

Primary Outcome Measure

Mean foveal thickness measured by SD-OCT [ Time Frame: 2 years ]